
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Divisions of Diagnostic Molecular Oncology [B. Z., A. O., T. M.] and Surgical Oncology [B. Z., K. Y., Y. T., M. M., T. M.], Cancer Research Institute, Kanazawa University, Kanazawa 920-0934, Japan
Purpose and Study Design: Recent studies have shown that ß-catenin translocated into the cell nucleus functions like an oncogene. Accumulating evidence suggests that activation of the ß-catenin oncogenic signaling cascade along with its twin, the K-ras cascade, may exert syngeneic or synergistic effects on tumor development and progression. In the study reported here, we analyzed oncogenic ß-catenin activation on the basis of its nuclear accumulation (NA) and compared the results with those of mutational activation of K-ras in 74 patients with colorectal cancer to determine whether the two oncogene-mediated signaling cascades interact.
Results: We found two distinct patterns of ß-catenin activation, i.e., diffuse NA in 20 cases (27%) and selective NA at the tumor invasion front (NAinv) in 19 cases (26%). The presence of the NAinv pattern was significantly correlated with advanced Dukes stage tumor (P = 0.0005) and the presence of distant metastases (P = 0.0064). K-ras proto-oncogene was mutated in the tumors of 31 cases (42%). Activated ß-catenin or K-ras was detected in most (78%) colorectal cancers analyzed, although a weak inverse correlation was found between the activities of the two oncogenes in the tumors. Importantly, most (7 of 8) patients with tumor showing both K-ras activation and the NAinv pattern of ß-catenin activation were in Dukes stage C at surgery, and half of them developed distant metastases to the liver and lungs.
Conclusion: The results suggest that although oncogenic activation of ß-catenin and K-ras is independent in the process of clinical cancer development, combined analysis of the two major oncogenes can detect most colorectal cancers and identify a subset of patients with poorer outcomes. Consequently, activation of either or both of these oncogenes may serve as a genetic marker for molecular diagnosis.
This article has been cited by other articles:
![]() |
J. C. Coffey, J. H. Wang, M. J. F. Smith, A. Laing, D. Bouchier-Hayes, T. G. Cotter, and H. P. Redmond Phosphoinositide 3-Kinase Accelerates Postoperative Tumor Growth by Inhibiting Apoptosis and Enhancing Resistance to Chemotherapy-induced Apoptosis: NOVEL ROLE FOR AN OLD ENEMY J. Biol. Chem., June 3, 2005; 280(22): 20968 - 20977. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ougolkov, B. Zhang, K. Yamashita, V. Bilim, M. Mai, S. Y. Fuchs, and T. Minamoto Associations Among {beta}-TrCP, an E3 Ubiquitin Ligase Receptor, {beta}-Catenin, and NF-{kappa}B in Colorectal Cancer J Natl Cancer Inst, August 4, 2004; 96(15): 1161 - 1170. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Baldus, S. P. Monig, S. Huxel, S. Landsberg, F.-G. Hanisch, K. Engelmann, P. M. Schneider, J. Thiele, A. H. Holscher, and H. P. Dienes MUC1 and Nuclear {beta}-Catenin Are Coexpressed at the Invasion Front of Colorectal Carcinomas and Are Both Correlated with Tumor Prognosis Clin. Cancer Res., April 15, 2004; 10(8): 2790 - 2796. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |